<DOC>
	<DOC>NCT01879917</DOC>
	<brief_summary>The purpose of this study is to investigate the effect and safety of liraglutide 1.8 mg once daily compared to placebo for 52 weeks on change in beta-cell function in patients with newly diagnosed type 1 diabetes as an adjunctive therapy to insulin treatment.</brief_summary>
	<brief_title>Liraglutide in Newly Onset Type 1 Diabetes.</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 1 diabetes according to WHO criteria diagnosed â‰¤ 6 weeks before visit 0 Age 18 40 years both inclusive Postprandial Cpeptide &gt; 0.2 nmol/l following sustacal meal test Able to understand the written patient information and to give informed consent Type 2 diabetes Body mass index &lt;20 kg/m2 Pregnancy or unwillingness to use safe contraceptives Compromised kidney function (eGFR &lt; 60 ml/min/1,73m2), dialysis or kidney transplantation at visit 0 Liver disease with elevated plasma alanine aminotransferase (ALT) &gt; three times the upper limit of normal at visit 0</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>c-peptide</keyword>
	<keyword>insulin</keyword>
	<keyword>hypoglycemia</keyword>
	<keyword>Newly onset</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Type 1</keyword>
	<keyword>Beta cell</keyword>
	<keyword>Autoimmune</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Meal test</keyword>
</DOC>